Anagram Therapeutics
Last verified 2026-05-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $250.0Mattributed |
|---|---|
| Latest round | series-b, $250.0M, 2026-05-08attributed |
| Founded | 2022 |
| Headquarters | Natick, MA |
| Industry | biotech |
| Stage | series-b+ |
| Website | anagramtherapeutics.com |
Anagram Therapeutics develops oral enzyme replacement therapies for rare digestive diseases driven by malabsorption. It targets patients with cystic fibrosis and exocrine pancreatic insufficiency. Lead candidate ANG003 is a non-porcine recombinant enzyme engineered to survive the gut, replacing legacy porcine extracts.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-08 | series-b | $250.0M | undisclosed |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $250.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $250.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | anagramtherapeutics.com, read 2026-05-25 |
| Description | self-reported | anagramtherapeutics.com, read 2026-05-25 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.